733 related articles for article (PubMed ID: 23255218)
1. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.
Boehm D; Calvanese V; Dar RD; Xing S; Schroeder S; Martins L; Aull K; Li PC; Planelles V; Bradner JE; Zhou MM; Siliciano RF; Weinberger L; Verdin E; Ott M
Cell Cycle; 2013 Feb; 12(3):452-62. PubMed ID: 23255218
[TBL] [Abstract][Full Text] [Related]
2. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation.
Li Z; Guo J; Wu Y; Zhou Q
Nucleic Acids Res; 2013 Jan; 41(1):277-87. PubMed ID: 23087374
[TBL] [Abstract][Full Text] [Related]
3. BET-Inhibitors Disrupt Rad21-Dependent Conformational Control of KSHV Latency.
Chen HS; De Leo A; Wang Z; Kerekovic A; Hills R; Lieberman PM
PLoS Pathog; 2017 Jan; 13(1):e1006100. PubMed ID: 28107481
[TBL] [Abstract][Full Text] [Related]
4. The KAT5-Acetyl-Histone4-Brd4 axis silences HIV-1 transcription and promotes viral latency.
Li Z; Mbonye U; Feng Z; Wang X; Gao X; Karn J; Zhou Q
PLoS Pathog; 2018 Apr; 14(4):e1007012. PubMed ID: 29684085
[TBL] [Abstract][Full Text] [Related]
5. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
J Virol; 2018 May; 92(10):. PubMed ID: 29343578
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of latent HIV-1 by inhibition of BRD4.
Zhu J; Gaiha GD; John SP; Pertel T; Chin CR; Gao G; Qu H; Walker BD; Elledge SJ; Brass AL
Cell Rep; 2012 Oct; 2(4):807-16. PubMed ID: 23041316
[TBL] [Abstract][Full Text] [Related]
7. HIV latency reversing agents act through Tat post translational modifications.
Khoury G; Mota TM; Li S; Tumpach C; Lee MY; Jacobson J; Harty L; Anderson JL; Lewin SR; Purcell DFJ
Retrovirology; 2018 May; 15(1):36. PubMed ID: 29751762
[TBL] [Abstract][Full Text] [Related]
8. A new BET on the control of HIV latency.
Karn J
Cell Cycle; 2013 Feb; 12(4):545-6. PubMed ID: 23370386
[No Abstract] [Full Text] [Related]
9. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein.
Bartholomeeusen K; Xiang Y; Fujinaga K; Peterlin BM
J Biol Chem; 2012 Oct; 287(43):36609-16. PubMed ID: 22952229
[TBL] [Abstract][Full Text] [Related]
10. P-TEFb as a target to reactivate latent HIV: two Brds are now in hand.
Rice AP
Cell Cycle; 2013 Feb; 12(3):392-3. PubMed ID: 23324342
[TBL] [Abstract][Full Text] [Related]
11. A Natural Product from Polygonum cuspidatum Sieb. Et Zucc. Promotes Tat-Dependent HIV Latency Reversal through Triggering P-TEFb's Release from 7SK snRNP.
Wang C; Yang S; Lu H; You H; Ni M; Shan W; Lin T; Gao X; Chen H; Zhou Q; Xue Y
PLoS One; 2015; 10(11):e0142739. PubMed ID: 26569506
[TBL] [Abstract][Full Text] [Related]
12. The Short Isoform of BRD4 Promotes HIV-1 Latency by Engaging Repressive SWI/SNF Chromatin-Remodeling Complexes.
Conrad RJ; Fozouni P; Thomas S; Sy H; Zhang Q; Zhou MM; Ott M
Mol Cell; 2017 Sep; 67(6):1001-1012.e6. PubMed ID: 28844864
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of CDK9 at Ser175 enhances HIV transcription and is a marker of activated P-TEFb in CD4(+) T lymphocytes.
Mbonye UR; Gokulrangan G; Datt M; Dobrowolski C; Cooper M; Chance MR; Karn J
PLoS Pathog; 2013; 9(5):e1003338. PubMed ID: 23658523
[TBL] [Abstract][Full Text] [Related]
14. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
[TBL] [Abstract][Full Text] [Related]
15. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
16. UHRF1 Suppresses HIV-1 Transcription and Promotes HIV-1 Latency by Competing with p-TEFb for Ubiquitination-Proteasomal Degradation of Tat.
Liang T; Zhang Q; Wu Z; Chen P; Huang Y; Liu S; Li L
mBio; 2021 Aug; 12(4):e0162521. PubMed ID: 34465029
[TBL] [Abstract][Full Text] [Related]
17. The mTOR Complex Controls HIV Latency.
Besnard E; Hakre S; Kampmann M; Lim HW; Hosmane NN; Martin A; Bassik MC; Verschueren E; Battivelli E; Chan J; Svensson JP; Gramatica A; Conrad RJ; Ott M; Greene WC; Krogan NJ; Siliciano RF; Weissman JS; Verdin E
Cell Host Microbe; 2016 Dec; 20(6):785-797. PubMed ID: 27978436
[TBL] [Abstract][Full Text] [Related]
18. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation.
Wu SY; Chiang CM
J Biol Chem; 2007 May; 282(18):13141-5. PubMed ID: 17329240
[TBL] [Abstract][Full Text] [Related]
19. Flow Cytometric Analysis of HIV-1 Transcriptional Activity in Response to shRNA Knockdown in A2 and A72 J-Lat Cell Lines.
Boehm D; Ott M
Bio Protoc; 2017 Jun; 7(11):. PubMed ID: 29082287
[TBL] [Abstract][Full Text] [Related]
20. BET bromodomain proteins are required for glioblastoma cell proliferation.
Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
